Table 2

Prevalence of at least one C282Y allelea in breast and nonbreast cancer cases in the transplant cohort compared with other population samples

Transplant cohortUnited States populationbTennesseec
Breast cancerd (n = 41) % (95% CI)eNonbreast cancerd (n = 129) % (95% CI)Overall (n = 5171) % (95% CI)All women (n = 2884) % (95% CI)Non-Hispanic white (n = 2016) % (95% CI)Overall (n = 169) % (95% CI)Non-Hispanic white (n = 118) % (95% CI)
36.6 (22.0–51.3)17.0 (10.5–23.4)6.6 (5.9–7.3)7.2 (6.3–8.1)12.4 (11.0–13.8)10.6 (6.0–15.2)12.7 (6.7–18.7)
  • a Includes C282Y homozygotes and heterozygotes (heterozygotes include C282Y/Wt + C282Y/H63D genotypes).

  • b Data from Steinberg et al. (22) .

  • c Kallianpur et al.9

  • d Both transplant categories include 2 patients who each had both breast cancer and leukemia diagnoses; nonbreast cancers include all hematological malignancies, two germ cell cancers and 1 aplastic anemia. The transplant cohort was 96% non-Hispanic whites.

  • e Values are percentage of patients with 95% confidence intervals (95% CI).